Mr. Kamal has been CEO of pharmaceutical benefit manager Magellan Rx since 2015, according to a March 27 news release from Prime Therapeutics. Prime Therapeutics acquired Magellan Rx from Centene in December 2022.
Prime Therapeutics, jointly owned by 19 Blue Cross Blue Shield companies, is integrating the two companies.
Prime CEO Ken Paula will continue in his role, according to the release.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
